Cizutamig clinical trials
Also written CND106.
How each study uses cizutamig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cizutamig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
Candid Therapeutics (4) · Ruijin Hospital (2) · Peking University First Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Shanghai EpimAb Biotherapeutics Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test cizutamig.
- Dec 2026A Study of Cizutamig in Systemic SclerosisEarly Phase 1 · Ruijin Hospital
- Jun 2027An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid ArthritisPhase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Studies
Open first, then newest update. How each study uses cizutamig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingPhase 1Candid TherapeuticsNCT07215650Written as Cizutamig
- Clinical Study of Cizutamig in Systemic Lupus ErythematosusRecruitingPhase 1Candid TherapeuticsNCT07215663Written as Cizutamig
- A Study of Cizutamig for Patients With Ulcerative ColitisNot yet recruitingEarly Phase 1Ruijin HospitalNCT07353450Written as cizutamig
- An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid ArthritisRecruitingPhase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06946199Written as Cizutamig
- A Study of Cizutamig in Systemic SclerosisNot yet recruitingEarly Phase 1Ruijin HospitalNCT07158996Written as Biological: cizutamig
- A Study of Cizutamig in Patients With Immunoglobulin A NephropathyEnrolling by invitationEarly Phase 1Peking University First HospitalNCT07135219Written as Biological: cizutamig
- Absolute Bioavailability Study of Cizutamig in Healthy Adult ParticipantsCompletedPhase 1Candid TherapeuticsNCT07236411Written as cizutamig
- A Phase 1 Study of Cizutamig in IgE Mediated DiseasesWithdrawnPhase 1Candid TherapeuticsNCT07408869Written as Cizutamig
- A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedPhase 1/2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT04735575Written as EMB-06
Codes
What other systems call cizutamig · ClinicalTrials.gg INT017548
- UNII (FDA) P5TLS56PWWCIZUTAMIGOne source FDA
- NCI Thesaurus C179632CizutamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P5TLS56PWW | CIZUTAMIG | One source FDA |
| NCI Thesaurus | C179632 | Cizutamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.